로딩 중…
StockDiggingStockDigging

IL DONG PHARMACEUTICAL CO., LTD.

249420· KOSPI
₩16,040-5.26%
2026-06-26

Price Chart

IL DONG PHARMACEUTICAL CO., LTD.+27.10%

Financials

Investment Metrics(as of 2026-06-26)

MetricValue
Size
Market Cap507.48B KRW
Revenue572.95B KRW
Net Income13.58B KRW
Total Assets562.10B KRW
Net Assets239.96B KRW
Employees1,056
Value
P/E37.36x
P/B2.11x
PEG0.06x
P/S0.89x
EV/EBITDA46.01x
FCF Yield1.05%
Profitability
ROE5.66%
ROA2.42%
Op. Margin2.26%
Revenue Growth4.43%
Earnings Growth617.82%
Financial Health
Debt Ratio234.25%
Total Debt124.63B KRW
FCF5.30B KRW
Cash35.93B KRW
Current Ratio0.99x
Net Debt/EBITDA6.85x
Dividend
Div. Yield1.18%
Performance
1Y Return27.10%
1M Return-26.76%
From 52W High-64.40%
1Y MDD-63.79%
Trading
Volume133,536 shares
Foreign Own.8.68%
Per Share
EPS1,143 KRW
BPS7,863 KRW

Company Info

CEO 윤웅섭, 이재준(공동 대표이사)
Employees 1,056
Founded 2016
HQ 서울특별시 서초구, KR

Established in 2016, this company manufactures and sells pharmaceuticals, raw materials, and health supplements. Its main products include the active vitamin AROAMIN series and the antibiotic FULUMARIN, which are sold domestically and internationally through various channels. The company conducts R&D for metabolic and respiratory disease treatments, with its COVID-19 treatment ID32124 (Xocova) having received approval in Japan, advancing its global new drug development and commercialization. Ildong Pharmaceutical was founded in 2016 and is headquartered in Seocho-gu, Seoul.